Biovitae focuses on infection control and prevention, as well as combating antimicrobial resistance.
Biovitae has raised $5.7M in total funding. The most recent round was Series A. The last funding was announced in April 2025.
Biovitae's investors include Angelini Ventures, Ulixes Capital, Azimut Direct, ENEA Tech e Biomedical.
Biovitae is headquartered in Salerno, Italy.
Biovitae focuses on infection control and prevention, as well as combating antimicrobial resistance.
Biovitae is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Biovitae — Funding & Investors." VCBacked, April 22, 2025, https://www.vcbacked.co/company/biovitae. Accessed September 30, 2026.
VCBacked. (2025). Biovitae — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/biovitae
{{cite web |title=Biovitae — Funding & Investors |url=https://www.vcbacked.co/company/biovitae |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated